HER2-TARGETED THERAPIES
News & Literature Highlights
March 2021
-
HER2-Targeted Therapies
Deceleration Capacity of Heart Rate Predicts Trastuzumab‐Related Cardiotoxicity in Patients With HER2‐Positive Breast Cancer: A Prospective Observational Study
Journal of Clinical Pharmacy and Therapeutics
-
HER2-Targeted Therapies
Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
Frontiers in Pharmacology
-
HER2-Targeted Therapies
Mechanisms and Potential Interventions Associated With the Cardiotoxicity of ErbB2-Targeted Drugs: Insights From in vitro, in vivo, and Clinical Studies in Breast Cancer Patients
Cellular and Molecular Life Sciences
February 2021
January 2021
-
HER2-Targeted Therapies
Real‐World Impact of Anti‐HER2 Therapy‐Related Cardiotoxicity in Patients With Advanced HER2‐Positive Breast Cancer
Asia-Pacific Journal of Clinical Oncology
December 2020
November 2020
-
HER2-Targeted Therapies
Cardiotoxicity Manifestations in Metastatic Breast Cancer Patients Treated With Trastuzumab as First Line
2020 ASCO Virtual Scientific Program
October 2020
September 2020
-
HER2-Targeted Therapies
Genotypes and Comorbidities Associated With Trastuzumab-Induced Cardiotoxicity in HER2+ Breast Cancer
Targeted Oncology
-
HER2-Targeted Therapies
Long-Term Follow-Up Assessment of Cardiac Safety in SAFE-HEaRt, a Clinical Trial Evaluating the Use of HER2-Targeted Therapies in Patients With HER2-Positive Breast Cancer and Compromised Heart Function
ASCO Annual Meeting 2020 (Abstract/Poster)
-
General Cardio-Oncology
The Role of Biomarkers to Evaluate Cardiotoxicity
Current Treatment Options in Oncology
-
General Cardio-Oncology
Preventing Today’s Survivors of Breast Cancer From Becoming Tomorrow’s Cardiac Patients
JCO Oncology Practice
-
General Cardio-Oncology
Innovation in Precision Cardio-Oncology During the Coronavirus Pandemic and Into a Post-pandemic World
Frontiers in Cardiovascular Medicine
August 2020
-
HER2-Targeted Therapies
Cardiotoxicity Surveillance and Risk of Heart Failure During HER2-Targeted Therapy
JACC: CardioOncology
-
HER2-Targeted Therapies
Effect at One Year of Adjuvant Trastuzumab for HER2+ Breast Cancer Combined with Radiation or an Anthracycline on Left Ventricular Ejection Fraction
American Journal of Cardiology
July 2020
-
HER2-Targeted Therapies
Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab
JACC: CardioOncology
-
HER2-Targeted Therapies
Trastuzumab Emtansine (T-DM1)-Associated Cardiotoxicity: Pooled Analysis in Advanced HER2-Positive Breast Cancer
European Journal of Cancer
-
HER2-Targeted Therapies
Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer
American Journal of Cardiology
June 2020
-
HER2-Targeted Therapies
HER2+ Breast Cancer Treatment and Cardiotoxicity: Monitoring and Management
Breast Cancer Research and Treatment
May 2020
-
HER2-Targeted Therapies
Long-Term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer
JAMA Cardiology
-
General Cardio-Oncology
Patients With Certain Cancers May Be at a Higher Risk for Atrial Fibrillation
The ASCO Post
-
General Cardio-Oncology
Metabolic Changes May Signal Development of Chemotherapy-Associated Cardiotoxicity
The ASCO Post
